Lumira Ventures | Cancer Breakthrough Fund
◆ Fund Size
$200M
◆ Check Size
◆ Location
Canada
◆ Portfolio
4 companies
◆ Activity
Statusactively investing
◆ Links
◆ Share this fund
◆ Investment Thesis
Mission-driven venture capital fund focused on funding innovative cancer companies, combining venture capital expertise with scientific networks of leading Canadian cancer charities
◆ About Lumira Ventures
The Cancer Breakthrough Fund is a partnership between Lumira Ventures and the Terry Fox Foundation designed to invest in mission-driven companies developing novel cancer therapies. The fund bridges philanthropic capital with venture expertise to support oncology innovation across preclinical, clinical, and commercial stages.
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Team
| Name | Title | Role | Links |
|---|---|---|---|
| Benjamin Rovinski, Ph.D. | Managing Director | — | |
| Brian J. Underdown, Ph.D. | Venture Partner | — | |
| Daniel Hetu | Managing Director | — | |
| Gerry Brunk | Managing Partner | — | |
| Lu Han, Ph.D. | Director, Business Development Asia Pacific | — | |
| Nikhil Thatte | Principal | — |
◆ Notable Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Cancer Breakthrough Fund invest in?
Cancer Breakthrough Fund invests in Biotech, Drug Discovery, Diagnostics, Digital Health and Medtech at the seed stage.
Which geographies does Cancer Breakthrough Fund focus on?
Cancer Breakthrough Fund focuses on Canada, and is headquartered in Canada.
What is Cancer Breakthrough Fund's typical check size?
Cancer Breakthrough Fund typically writes checks of $5M to $15M.